45 related articles for article (PubMed ID: 10854140)
1. A phase II study of temozolomide in hormone-refractory prostate cancer.
van Brussel JP; Busstra MB; Lang MS; Catsburg T; Schröder FH; Mickisch GH
Cancer Chemother Pharmacol; 2000; 45(6):509-12. PubMed ID: 10854140
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).
Trudeau ME; Crump M; Charpentier D; Yelle L; Bordeleau L; Matthews S; Eisenhauer E
Ann Oncol; 2006 Jun; 17(6):952-6. PubMed ID: 16565212
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
5. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
6. A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).
Hervonen P; Lehtinen T; Tammela TL; Kellokumpu-Lehtinen P
J Exp Clin Cancer Res; 2002 Jun; 21(2):177-80. PubMed ID: 12148574
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.
Christodoulou C; Bafaloukos D; Kosmidis P; Samantas E; Bamias A; Papakostas P; Karabelis A; Bacoyiannis C; Skarlos DV;
Ann Oncol; 2001 Feb; 12(2):249-54. PubMed ID: 11300333
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).
Dziadziuszko R; Ardizzoni A; Postmus PE; Smit EF; Price A; Debruyne C; Legrand C; Giaccone G;
Eur J Cancer; 2003 Jun; 39(9):1271-6. PubMed ID: 12763216
[TBL] [Abstract][Full Text] [Related]
11. Palliative chemotherapy with trofosfamide in advanced prostate cancer.
Salminen EK; Sundström J; Nikkanen V
Anticancer Res; 2006; 26(1B):539-42. PubMed ID: 16739316
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
[TBL] [Abstract][Full Text] [Related]
13. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of temozolomide in advanced untreated pancreatic cancer.
Moore MJ; Feld R; Hedley D; Oza A; Siu LL
Invest New Drugs; 1998; 16(1):77-9. PubMed ID: 9740547
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
17. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
[TBL] [Abstract][Full Text] [Related]
18. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
